Next Article in Journal
Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
Previous Article in Journal
Resveratrol-Loaded Lipid Nanocarriers: Correlation between In Vitro Occlusion Factor and In Vivo Skin Hydrating Effect
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Pharmaceutics
Volume 9
Issue 4
10.3390/pharmaceutics9040059
pharmaceutics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Correction to Pharmaceutics 2017, 9(3), 27.
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Correction

Correction: Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics, 2017, 9(3), 27

by
Akihiko Ono
1,2,†,
Sayami Ito
1,2,†,
Shun Sakagami
1,2,
Hideo Asada
3,
Mio Saito
4,
Ying-Shu Quan
4,
Fumio Kamiyama
4,
Sachiko Hirobe
2,† and
Naoki Okada
1,2,5,*
1
Project for Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
2
Laboratory of Biotechnology and Therapeutics, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
3
Department of Dermatology, Nara Medical University, 840 Shin-cho, Kashihara, Nara 634-8522, Japan
4
CosMED Pharmaceutical Co. Ltd., 32 Higashikujokawanishi-cho, Minami-ku, Kyoto 601-8014, Japan
5
Laboratory of Vaccine and Immune Regulation, Graduate School of Pharmaceutical Sciences, Osaka University, 1-6 Yamadaoka, Suita, Osaka 565-0871, Japan
*
Author to whom correspondence should be addressed.
†
These authors contribute equally to this work.
Pharmaceutics 2017, 9(4), 59; https://doi.org/10.3390/pharmaceutics9040059
Submission received: 13 December 2017 / Revised: 13 December 2017 / Accepted: 13 December 2017 / Published: 18 December 2017
Browse Figures
Versions Notes
The authors wish to make a change to their published paper [1]. The unit in the y axis of Figure 5C should be changed from “%” to “g/h·m2”. Therefore, we wish to replace the figure with the correct one below (Figure 1C).
The authors apologize for any inconvenience caused. The changes do not affect the scientific results. The manuscript will be updated and the original will remain online on the article webpage (https://www.mdpi.com/1999-4923/9/3/27), with a reference to this addendum.

References

  1. Ono, A.; Ito, S.; Sakagami, S.; Asada, H.; Saito, M.; Quan, Y.S.; Kamiyama, F.; Hirobe, S.; Okada, N. Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics 2017, 9, 27. [Google Scholar] [CrossRef]
Pharmaceutics 09 00059 g001a 550Pharmaceutics 09 00059 g001b 550
Figure 1. Antigen delivery images, dissolution of MNs, skin puncturability, and safety using faster-dissolving MN patches on human skin. (A) F-OVA-loaded MN patches were applied to the resected human dermal tissues. In the fluorescence images, the area between the top line and the middle line represents the stratum corneum, the area between the middle line and the bottom line represents the living epidermis, and the dermis is located under the bottom line. Green and blue fluorescence indicate F-OVA and nucleus (DAPI), respectively; (B) Placebo CMC-MN and HN-MN patches were each applied to the skin of upper outer arm of 19 healthy volunteers (14 male and five female) for the indicated times. After removal of MN patches, the remaining MNs on each CMC-MN and HN-MN patch were photographed using a stereoscopic microscope; (C) After MN patch applications of 30 min, TEWL at the application site was measured immediately after MN patch removal. Data are expressed as mean ± SD of results from three measurements; (D) Skin irritation caused by application of MN patches was assessed in accordance with the ICDRG score. Each plot expresses the score of an individual subject. Four photographs show the site judged as +? “doubtful reaction; faint erythema only.”
Figure 1. Antigen delivery images, dissolution of MNs, skin puncturability, and safety using faster-dissolving MN patches on human skin. (A) F-OVA-loaded MN patches were applied to the resected human dermal tissues. In the fluorescence images, the area between the top line and the middle line represents the stratum corneum, the area between the middle line and the bottom line represents the living epidermis, and the dermis is located under the bottom line. Green and blue fluorescence indicate F-OVA and nucleus (DAPI), respectively; (B) Placebo CMC-MN and HN-MN patches were each applied to the skin of upper outer arm of 19 healthy volunteers (14 male and five female) for the indicated times. After removal of MN patches, the remaining MNs on each CMC-MN and HN-MN patch were photographed using a stereoscopic microscope; (C) After MN patch applications of 30 min, TEWL at the application site was measured immediately after MN patch removal. Data are expressed as mean ± SD of results from three measurements; (D) Skin irritation caused by application of MN patches was assessed in accordance with the ICDRG score. Each plot expresses the score of an individual subject. Four photographs show the site judged as +? “doubtful reaction; faint erythema only.”
Pharmaceutics 09 00059 g001aPharmaceutics 09 00059 g001b

Share and Cite

MDPI and ACS Style

Ono, A.; Ito, S.; Sakagami, S.; Asada, H.; Saito, M.; Quan, Y.-S.; Kamiyama, F.; Hirobe, S.; Okada, N. Correction: Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics, 2017, 9(3), 27. Pharmaceutics 2017, 9, 59. https://doi.org/10.3390/pharmaceutics9040059

AMA Style

Ono A, Ito S, Sakagami S, Asada H, Saito M, Quan Y-S, Kamiyama F, Hirobe S, Okada N. Correction: Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics, 2017, 9(3), 27. Pharmaceutics. 2017; 9(4):59. https://doi.org/10.3390/pharmaceutics9040059

Chicago/Turabian Style

Ono, Akihiko, Sayami Ito, Shun Sakagami, Hideo Asada, Mio Saito, Ying-Shu Quan, Fumio Kamiyama, Sachiko Hirobe, and Naoki Okada. 2017. "Correction: Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics, 2017, 9(3), 27" Pharmaceutics 9, no. 4: 59. https://doi.org/10.3390/pharmaceutics9040059

APA Style

Ono, A., Ito, S., Sakagami, S., Asada, H., Saito, M., Quan, Y. -S., Kamiyama, F., Hirobe, S., & Okada, N. (2017). Correction: Development of Novel Faster-Dissolving Microneedle Patches for Transcutaneous Vaccine Delivery. Pharmaceutics, 2017, 9(3), 27. Pharmaceutics, 9(4), 59. https://doi.org/10.3390/pharmaceutics9040059

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop